---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-008540"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:31:26.597101+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MAIA plans Phase 3 pivotal trial of THIO+CPI vs chemo in NSCLC patients

## Summary
- Phase 3 trial THIO-104 to enroll up to 300 patients with third-line NSCLC.
- Primary endpoint is overall survival; THIO sequenced with checkpoint inhibitor vs investigator's choice chemo.
- Patient enrollment expected to begin H2 2025 in Asia, Europe, and U.S.
- Based on THIO-101 Phase 2 data that consistently outperformed standard options.
- Trial designed to support FDA commercial approval of THIO.

## SEC filing metadata
- accession: 0001493152-25-008540
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225008540/0001493152-25-008540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225008540/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-008540
- JSON: https://secwatch.observer/filing/0001493152-25-008540.json
- Plain text: https://secwatch.observer/filing/0001493152-25-008540.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.